network member

UC San Francisco

San Francisco, California

About Network Member

Currently Enrolling

HCRN-GU21-551

ENHANCE (Elevated NKG2A and HLA-E Amplify NK/CD8 Checkpoint Engagers): A Phase 2 Trial of Durvalumab (MEDI4736) plus Monalizumab in Non-Muscle-Invasive Bladder Cancer

Cancer areas:Bladder

Icahn School of Medicine at Mount Sinai

Moffitt Cancer Center

Rutgers Cancer Institute

UC San Francisco

Weill Cornell Medicine

See clinicaltrials.gov

Enrollment Closed

HCRN-BRE21-516

BRIDGET: Secondary BRain metastases prevention after Isolated intracranial progression on Trastuzumab/Pertuzumab or T-DM1 in patients with aDvanced human epidermal Growth factor receptor 2+ brEast cancer with the addition of Tucatinib

Cancer areas:Breast

Dana-Farber Cancer Institute

Duke Cancer Institute

MD Anderson Cancer Center

Novant Health Oncology Specialists

Providence Cancer Institute

Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine

The Ohio State University

UC San Francisco

University of Michigan Rogel Cancer Center

See clinicaltrials.gov

Enrollment Closed

TBCRC047

Innovative Combination Immunotherapy for Metastatic Triple Negative Breast Cancer (TNBC): A Multicenter, Multi-Arm Translational Breast Cancer Research Consortium Study

Hope Rugo

Cancer areas:Breast